

BUMRUNGRAD HOSPITAL
THAILAND / HEALTH CARE SERVICES

BH TB

BUY

FROM HOLD

Time to reassess valuation

- คาดกำไรปกติ 4Q24 จะโต 4% y-y เป็น 1.77 พัน ลบ.
- มูลค่าหลักทรัพย์ตามราคาตลาดของ BH ลดลง 72 พัน ลบ. ซึ่งน่าจะสะท้อนกำไรที่คาดว่าจะลดลง 400-500 ลบ. ต่อปีจากผู้ป่วยชาวคูเวตที่หายไปและผลกระทบจากค่าใช้จ่ายสำรอง (ถ้ามี) เรียบร้อยแล้ว
- ปรับเพิ่มคำแนะนำเป็นซื้อที่ราคาเป้าหมาย 220 บาท (DCF)

TARGET PRICE	THB220.00
CLOSE	THB187.50
UP/DOWNSIDE	+17.3%
PRIOR TP	THB285.00
CHANGE IN TP	-22.8%
TP vs CONSENSUS	-11.6%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	25,376	25,552	26,316	27,776
Net profit	7,006	7,667	7,906	8,082
EPS (THB)	8.80	9.63	9.93	10.16
vs Consensus (%)	-	2.0	2.6	2.2
EBITDA	9,509	10,246	10,618	11,065
Recurring net profit	6,918	7,667	7,906	8,082
Core EPS (THB)	8.69	9.63	9.93	10.16
Chg. In EPS est. (%)	-	0.0	(0.5)	(1.6)
EPS growth (%)	40.0	10.8	3.1	2.2
Core P/E (x)	21.6	19.5	18.9	18.5
Dividend yield (%)	2.0	2.4	3.1	3.2
EV/EBITDA (x)	14.6	13.2	12.5	11.6
Price/book (x)	6.3	5.4	4.8	4.3
Net debt/Equity (%)	(44.2)	(50.7)	(54.8)	(59.5)
ROE (%)	31.8	29.7	26.8	24.6

คาดการณ์รายได้จะลดลงและอัตรากำไรจะปรับตัวดีขึ้นใน 4Q24

เราคาดว่ารายได้จะลดลง 3% y-y ใน 4Q24 (ค่อนข้างใกล้เคียงกับประมาณการของผู้บริหารที่ระหว่าง -3% ถึงทรงตัว y-y) รายได้ผู้ป่วยต่างชาติน่าจะลดลง 5% y-y โดยมีปัจจัยกดดันจากการชะลอตัวของรายได้ผู้ป่วยชาวคูเวตและ UAE ในขณะที่รายได้ผู้ป่วยชาวไทยน่าจะค่อนข้างทรงตัว y-y เราคาดว่า EBITDA margin จะปรับตัวดีขึ้นเล็กน้อยเป็น 37% (เทียบกับ 36% ใน 4Q23) จากการควบคุมต้นทุนที่ดีขึ้นและการปรับราคาค่ารักษายาบาลเฉลี่ย 3% ในปี 2024 ดังนั้นเราจึงคาดว่ากำไรปกติจะสูงขึ้น 4% y-y เป็น 1.77 พัน ลบ.

รายได้ผู้ป่วยชาวตะวันออกกลาง (ME) จะกลับสู่ระดับปกติในปี 2025


เราคาดว่ารายได้จากผู้ป่วย ME จะลดลง 10% จาก 6.8 พัน ลบ. ในปี 2023 (สัดส่วนรายได้ 27%) เป็น 6.1 พัน ลบ. (สัดส่วนรายได้ 24%) ในปี 2024 ซึ่งน่าจะกลายเป็นฐานรายได้ใหม่ในปี 2025 ดังนั้นเราจึงสรุปได้ว่าผู้ป่วยชาวคูเวตที่หายไปและการชะลอตัวของผู้ป่วยชาว UAE ซึ่งจะทำให้รายได้ลดลงประมาณ 1.0 พัน ลบ. อาจหมายถึงกำไรที่ลดลง 400-500 ลบ. อย่างไรก็ตามกำไรของ BH ได้ปรับตัวลดลงแรงถึง 33% จากจุดสูงสุดที่ 278 บาท/หุ้นซึ่งทำให้เสียมูลค่าหลักทรัพย์ตามราคาตลาด 72 พัน ลบ. ในช่วง 4 เดือนที่ผ่านมา เราคิดว่าตัวเลขที่ลดลงดังกล่าวไม่สมเหตุสมผลเมื่อพิจารณาจากกำไรที่ลดลง 400-500 ลบ. ต่อปี ทั้งนี้เราคาดว่ารายได้ผู้ป่วยต่างชาติจะสูงขึ้น 2% ในปี 2025 โดยมีปัจจัยผลักดันจากรายได้ผู้ป่วยต่างชาติที่ไม่ได้มาจาก ME (+6-7% ในช่วงปี 2024-25E) เป็นหลัก

บัญชีลูกหนี้ของผู้ป่วยชาวคูเวตไม่ใช่ประเด็นสำคัญที่น่ากังวล

บัญชีลูกหนี้ของผู้ป่วยชาวคูเวตเป็นอีกหนึ่งประเด็นที่น่ากังวลโดยบริษัท อาจต้องตั้งสำรองหลังรัฐบาลคูเวตอาจเลื่อนการชำระเงินออกไป แม้ว่า BH จะไม่ได้เปิดเผยตัวเลขบัญชีลูกหนี้ที่แท้จริงออกมา เราคาดว่าตัวเลขอาจอยู่ที่ไม่เกิน 10-15% (จากสัดส่วนรายได้ผู้ป่วยชาวคูเวตที่ 5% ในปี 2023) ของบัญชีลูกหนี้คงค้างที่ 4.0 พัน ลบ. ณ สิ้นไตรมาส 3Q24 หรือ 400-600 ลบ. ดังนั้นเราจึงมองว่าสำรอง (ถ้ามี) จะไม่ใช่ประเด็นสำคัญที่ต้องกังวลเมื่อเทียบกับมูลค่าหลักทรัพย์ตามราคาตลาดของ BH ที่ลดลง

ปรับเพิ่มคำแนะนำเป็นซื้อ อัตราส่วนความเสี่ยงต่อผลตอบแทนกำลังเป็นบวก

เราประมาณการกำไรปี 2024 ของเราและปรับลดประมาณการกำไรปี 2025-26 ลง 1% ซึ่งทำให้ได้ราคาเป้าหมายปี 2025 ใหม่ที่ 220 บาท (DCF) เราปรับเพิ่มคำแนะนำสำหรับ BH เป็นซื้อเนื่องจากเราเชื่อว่าราคาหุ้นในปัจจุบันได้สะท้อนข่าวร้ายเกือบทั้งหมดไปแล้ว ทั้งนี้เราคาดว่ากำไรปี 2025 จะโต 3% เป็น 7.9 พัน ลบ. ถ้ารัฐบาลคูเวตกลับมาอนุญาตให้ส่งต่อผู้ป่วยมารักษาในประเทศไทยอีกครั้งจะเป็นปัจจัยบวกต่อกำไรและราคาหุ้นของบริษัท



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(2.8)	(9.4)	(22.5)
Relative to country (%)	5.4	4.7	(13.4)
Mkt cap (USD m)	4,434		
3m avg. daily turnover (USD m)	24.2		
Free float (%)	65		
Major shareholder	Thai NVDR (13%)		
12m high/low (THB)	284.00/171.50		
Issued shares (m)	922.70		

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

Fundamental Investment Analyst on Securities; License no. 080523
teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากต้นฉบับภาษาอังกฤษ ที่ออกรายงานเมื่อวันที่ 24 กุมภาพันธ์ 2025

<div><h3>Investment thesis</h3><p>We think BH’s operations are on an upward trend. International patient revenue should continue to improve on the back of normalized strong demand for medical tourism.</p><p>BH’s EBITDA margin should be on an upward trend since its hospitals have started to reduce their medical discount rate. Plus, international patients, which usually command a higher EBITDA margin than Thai patients, are beginning to recover in terms of volume.</p><p>However, the absence of Kuwaiti patients from the government cutting the guarantee of payment (GOP) for its citizens to seek treatments overseas has pressured revenue growth in 2024. BH is likely to be one of the approved hospitals selected by the Kuwaiti government, in our view. This should be finalized by 2025.</p></div> <div><h3>Company profile</h3><p>BH is a leading private hospital (580 licensed beds) in the premium segment.</p><p>www.bumrungrad.com</p></div>	<div><h3>Principal activities (revenue, 2023)</h3><div><div><div>■ Thai patient revenue - 32.9 %</div><div>■ International patient revenue - 66.8 %</div><div>■ Other revenue - 0.3 %</div></div></div><div><p>Source: Bumrungrad Hospital</p></div><div><h3>Major shareholders</h3><div><div><div>■ Thai NVDR - 12.9 %</div><div>■ Bangkok Insurance - 11.2 %</div><div>■ UOB Kay Hian (Hong Kong) - 9.1 %</div><div>■ Bangkok Bank - 6.7 %</div><div>■ Others - 60.0 %</div></div></div><div><p>Source: Bumrungrad Hospital</p></div></div></div>
---	---

Catalysts

Key growth drivers include 1) a new market including patients from Saudi Arabia and China; 2) the new hospital in Phuket, which will unlock growth from the standalone model; and 3) the vital life business (Wellness), which has a high margin compared to traditional healthcare.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.

Event calendar

Date	Event
Feb 2025	4Q24 results announcement

Key assumptions


	2024E	2025E	2026E
	(%)	(%)	(%)
OPD volume growth	0	0	3
OPD revenue / patient growth	1	3	3
IPD volume growth	0	0	3
IPD revenue / patient growth	0	3	3

Source: FSSIA estimates


Earnings sensitivity

- For every 1% increase in patient volume, we project 2025 earnings to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2025 earnings to rise by 4%, and vice versa, all else being equal.


Source: FSSIA estimates

Exhibit 1: Middle East patient revenue


Sources: BH; FSSIA estimates

Exhibit 2: Non-Middle East international patient revenue


Sources: BH; FSSIA estimates

Exhibit 3: International patient revenue


Sources: BH; FSSIA estimates

Exhibit 4: Thai patient revenue

Sources: BH; FSSIA estimates


Exhibit 5: International patient revenue, quarterly

Sources: BH; FSSIA estimates

Exhibit 6: Thai patient revenue, quarterly


Sources: BH; FSSIA estimates

Exhibit 7: EBITDA margin, quarterly



Sources: BH; FSSIA estimates

Exhibit 8: Core profit, quarterly



Sources: BH; FSSIA estimates

Exhibit 9: BH – 4Q24 results preview

	4Q23	1Q24	2Q24	3Q24	4Q24E	Change		2024E	Change
	(THB m)	(THB m)	(THB m)	(THB m)	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)
Sales	6,516	6,537	6,303	6,405	6,295	(2)	(3)	25,552	1
COGS (incl. depreciation)	(3,332)	(3,146)	(3,008)	(3,089)	(3,065)	(1)	(8)	(12,312)	(5)
Gross profit	3,184	3,391	3,294	3,316	3,229	(3)	1	13,240	6
SG&A	(1,140)	(1,020)	(1,007)	(1,003)	(1,163)	16	2	(4,190)	0
Operating profit	2,044	2,371	2,288	2,313	2,066	(11)	1	9,049	9
Net other income	29	29	28	41	30	(27)	3	127	15
Interest income	49	61	79	74	74	0	51	285	102
Interest expense	(1)	(2)	(2)	(2)	(2)	0	91	(8)	243
Pretax profit	2,121	2,459	2,393	2,426	2,168	(11)	2	9,453	11
Income Tax	(408)	(469)	(432)	(424)	(390)	(8)	(4)	(1,724)	9
Share gain/loss from JV	(0)	(0)	(0)	(0)	0				
Share gain/loss from associates	(0)	(0)	(0)	(0)	0			(1)	5
Minority interest	(11)	(15)	(24)	(12)	(11)	(4)	3	(61)	25
Core profit	1,702	1,975	1,937	1,990	1,766	(11)	4	7,667	11
Extraordinaries, GW & FX	19	10	(5)	(34)	0			0	
Reported net profit	1,721	1,985	1,932	1,955	1,766	(10)	3	7,667	9
Outstanding shares (m)	796	796	796	796	796	0	0	796	0
Core EPS (THB)	2.14	2.48	2.43	2.50	2.22	(11)	4	9.63	11
EPS (THB)	2.16	2.49	2.43	2.46	2.22	(10)	3	9.63	9
COGS (excl. depreciation)	3,058	2,879	2,742	2,820	2,797	(1)	(9)	11,243	(5)
Depreciation	274	267	267	269	269	0	(2)	1,069	(3)
EBITDA	2,348	2,667	2,582	2,623	2,365	(10)	1	10,246	8

Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)
Gross margin	49	52	52	52	51	(0)	2	52	3
SG&A/Revenue	17	16	16	16	18	3	1	16	(0)
EBITDA margin	36	41	41	41	37	(3)	2	40	3
Net profit margin	26	30	31	31	28	(2)	2	30	2

Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)	(y-y %)
Hospital revenue growth	9	8	4	(5)	(3)
OPD revenue growth	2	8	9	0	0
IPD revenue growth	16	8	0	0	0
International patient revenue growth	12	7	5	(7)	(5)
Thai patient revenue growth	3	9	2	(1)	(0)

Sources: BH; FSSIA estimates

Exhibit 10: Changes in key assumptions

	Current			Previous			Change		
	2024E (THB b)	2025E (THB b)	2026E (THB b)	2024E (THB b)	2025E (THB b)	2026E (THB b)	2024E (%)	2025E (%)	2026E (%)
OPD patient revenue	12.5	12.9	13.7	12.5	13.0	13.8	0.0	(1.0)	(1.0)
IPD patient revenue	13.0	13.3	14.0	13.0	13.6	14.4	(0.6)	(1.6)	(2.5)
Thai patient revenue	8.6	8.9	9.3	8.6	9.0	9.3	(0.4)	(0.4)	(0.4)
International patient revenue	16.9	17.3	18.4	16.9	17.6	18.9	(0.3)	(1.7)	(2.5)
Revenue	25.6	26.3	27.8	25.6	26.7	28.3	(0.3)	(1.3)	(1.8)
EBITDA margin (%)	40.1	40.3	39.8	40.6	40.6	40.1	(0.5)	(0.2)	(0.2)
Core profit	7.7	7.9	8.1	7.7	7.9	8.2	0.0	(0.5)	(1.6)

Note: Change of items in percentage terms are represented in ppt change


Source: FSSIA estimates

Exhibit 11: DCF valuation

Cost of equity assumptions		(%)	Cost of debt assumptions		(%)
Risk-free rate		3.0	Pre-tax cost of debt		3.5
Market risk premium		8.0	Marginal tax rate		20.0
Stock beta		0.7			
Cost of equity, Ke		8.6	Net cost of debt, Kd		2.8
Weight applied		87.0	Weight applied		13.0
WACC		7.8			
DCF valuation estimate		(THB b)	(THB/share)	Comments	
NPV		61.8	66.9	WACC 7.8%, Risk-free rate 3%, Risk premium 8%	
Terminal value		124.3	134.7	Terminal growth 3%	
Cash & liquid assets		17.4	18.9	At end-2025E	
Investments		0.0	0.0	At end-2025E	
Debt		(0.1)	(0.1)	At end-2025E	
Minorities		(0.4)	(0.5)	At end-2025E	
Residual ordinary equity		203.0	220.0		


Source: FSSIA estimates

Exhibit 12: One-year forward rolling P/E band



Sources: Bloomberg; FSSIA estimates

Exhibit 13: One-year forward rolling P/BV band



Sources: Bloomberg; FSSIA estimates

Exhibit 14: Peer comparisons as of 21 Feb 2025

Company	BBG	Rec	----- Share price -----			Market Cap (USD m)	----- PE -----		----- ROE -----		----- PBV -----		--- EV/ EBITDA ---	
			Current (LCY)	Target (LCY)	Upside (%)		24E (x)	25E (x)	24E (%)	25E (%)	24E (x)	25E (x)	24E (x)	25E (x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	23.30	36.50	56.7	11,015	23.2	21.0	16.4	17.1	3.7	3.5	14.3	13.0
Bumrungrad Hospital	BH TB	BUY	187.50	220.00	17.3	4,434	19.5	18.9	29.7	26.8	5.4	4.8	13.2	12.5
Bangkok Chain Hospital	BCH TB	BUY	15.60	20.00	28.2	1,157	31.6	24.5	9.6	11.8	3.0	2.8	14.9	12.1
Chularat Hospital	CHG TB	BUY	2.28	3.40	49.1	746	24.4	19.9	13.4	15.6	3.2	3.0	13.2	11.1
Patransit Healthcare Group	PHG TB	BUY	14.00	21.00	50.0	125	14.5	12.8	14.3	15.1	2.0	1.9	6.6	6.1
Praram 9 Hospital	PR9 TB	BUY	23.20	30.00	29.3	543	25.6	22.4	13.6	14.3	3.4	3.1	14.4	12.5
Thonburi Healthcare Group	THG TB	HOLD	13.40	40.00	198.5	338	22.7	14.2	4.9	7.6	1.1	1.1	10.5	8.7
Ramkhamhaeng Hospital	RAM TB	BUY	20.50	44.00	114.6	732	14.7	12.5	8.9	10.0	1.3	1.2	20.2	15.9
Srivichai Vejvivat	VIH TB	BUY	7.50	14.00	86.7	144	14.3	12.4	10.1	10.4	1.3	1.2	5.7	6.2
Rajthanee Hospital	RJH TB	n/a	18.60	n/a	n/a	159	10.7	11.8	25.7	22.7	2.6	2.4	9.6	9.3
Ekachai Medical Care	EKH TB	n/a	6.20	n/a	n/a	155	15.4	15.6	12.4	11.8	1.9	1.9	9.5	9.3
Thailand average						19,548	19.7	16.9	14.4	14.8	2.6	2.4	12.0	10.6
Regional														
Ramsay Health Care	RHC AU	n/a	34.30	n/a	n/a	5,033	27.6	26.1	6.5	6.1	1.6	1.6	8.8	8.6
Ihh Healthcare Bhd	IHH SP	n/a	2.18	n/a	n/a	14,319	32.7	31.0	6.9	6.7	2.1	2.0	13.9	12.8
Ryman Healthcare	RYM NZ	n/a	4.31	n/a	n/a	1,583	10.8	18.6	7.0	3.8	0.6	0.6	15.0	15.1
Apollo Hospitals Enterprise	APHS IN	n/a	6,318	n/a	n/a	10,364	96.9	62.3	14.1	18.9	12.9	11.1	39.5	31.1
Kpj Healthcare Berhad	KPJ MK	n/a	2.54	n/a	n/a	2,514	36.7	32.0	12.3	13.3	4.4	4.1	16.1	14.8
Raffles Medical Group	RFMD SP	n/a	0.83	n/a	n/a	1,224	24.4	22.6	6.6	7.0	1.6	1.5	11.5	10.9
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,430	n/a	n/a	2,083	30.2	27.3	18.8	18.8	5.2	4.7	18.4	16.6
Aier Eye Hospital Group	300015 CH	n/a	13.94	n/a	n/a	17,699	34.5	30.6	17.9	17.8	5.9	5.2	20.7	18.4
Regional average						54,819	36.7	31.3	11.3	11.5	4.3	3.8	18.0	16.0
Overall average						74,366	26.9	23.0	13.1	13.5	3.3	3.0	14.5	12.9

Sources: Bloomberg; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	20,721	25,376	25,552	26,316	27,776
Cost of goods sold	(11,099)	(12,895)	(12,312)	(12,657)	(13,543)
Gross profit	9,621	12,481	13,240	13,659	14,233
Other operating income	187	111	127	131	135
Operating costs	(3,798)	(4,180)	(4,190)	(4,289)	(4,583)
Operating EBITDA	7,127	9,509	10,246	10,618	11,065
Depreciation	(1,117)	(1,097)	(1,069)	(1,118)	(1,280)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	6,010	8,412	9,177	9,500	9,785
Net financing costs	42	139	277	280	340
Associates	(1)	(1)	(1)	(1)	(1)
Recurring non-operating income	(1)	(1)	(1)	(1)	(1)
Non-recurring items	(3)	88	0	0	0
Profit before tax	6,049	8,638	9,452	9,779	10,125
Tax	(1,072)	(1,583)	(1,724)	(1,809)	(1,974)
Profit after tax	4,977	7,055	7,728	7,970	8,150
Minority interests	(39)	(49)	(61)	(65)	(68)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	4,938	7,006	7,667	7,906	8,082
Non-recurring items & goodwill (net)	3	(88)	0	0	0
Recurring net profit	4,941	6,918	7,667	7,906	8,082
Per share (THB)					
Recurring EPS *	6.21	8.69	9.63	9.93	10.16
Reported EPS	6.21	8.80	9.63	9.93	10.16
DPS	3.20	3.69	4.50	5.78	5.96
Diluted shares (used to calculate per share data)	796	796	796	796	796
Growth					
Revenue (%)	66.3	22.5	0.7	3.0	5.5
Operating EBITDA (%)	158.5	33.4	7.8	3.6	4.2
Operating EBIT (%)	281.0	40.0	9.1	3.5	3.0
Recurring EPS (%)	287.9	40.0	10.8	3.1	2.2
Reported EPS (%)	306.2	41.9	9.4	3.1	2.2
Operating performance					
Gross margin inc. depreciation (%)	46.4	49.2	51.8	51.9	51.2
Gross margin exc. depreciation (%)	51.8	53.5	56.0	56.2	55.8
Operating EBITDA margin (%)	34.4	37.5	40.1	40.3	39.8
Operating EBIT margin (%)	29.0	33.1	35.9	36.1	35.2
Net margin (%)	23.8	27.3	30.0	30.0	29.1
Effective tax rate (%)	17.7	18.5	18.2	18.5	19.5
Dividend payout on recurring profit (%)	51.5	42.5	46.7	58.2	58.7
Interest cover (X)	(141.7)	(60.7)	(33.2)	(33.9)	(28.7)
Inventory days	11.9	10.6	11.5	11.1	10.9
Debtor days	36.3	50.8	63.0	61.1	57.9
Creditor days	34.6	33.5	34.2	32.9	32.4
Operating ROIC (%)	40.6	52.9	53.6	53.7	54.2
ROIC (%)	39.1	51.0	51.6	51.8	52.2
ROE (%)	26.7	31.8	29.7	26.8	24.6
ROA (%)	21.9	25.6	24.0	22.1	20.4
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)					
Thai patient revenue	7,536	8,348	8,581	8,925	9,282
International patient revenue	13,110	16,948	16,890	17,311	18,414
Other revenue	75	80	80	80	80

Sources: Bumrungrad Hospital; FSSIA estimates

Financial Statements

Bumrungrad Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	4,941	6,918	7,667	7,906	8,082
Depreciation	1,117	1,097	1,069	1,118	1,280
Associates & minorities	-	-	-	-	-
Other non-cash items	26	(16)	61	65	68
Change in working capital	131	(1,021)	(14)	106	212
Cash flow from operations	6,216	6,978	8,784	9,194	9,642
Capex - maintenance	(1,170)	(1,617)	(1,533)	(1,579)	(1,389)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	0	(12)	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(1,170)	(1,629)	(1,533)	(1,579)	(1,389)
Dividends paid	(2,543)	(2,938)	(3,581)	(4,600)	(4,743)
Equity finance	0	0	0	0	0
Debt finance	(8)	28	0	0	0
Other financing cash flows	(155)	31	0	0	0
Cash flow from financing	(2,705)	(2,880)	(3,581)	(4,600)	(4,743)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	2,341	2,469	3,670	3,015	3,510
Free cash flow to firm (FCFF)	5,049.59	5,351.60	7,258.83	7,623.06	8,261.36
Free cash flow to equity (FCFE)	4,882.92	5,407.78	7,250.63	7,614.86	8,253.16

Per share (THB)

FCFF per share	5.47	5.80	7.87	8.26	8.95
FCFE per share	5.29	5.86	7.86	8.25	8.94
Recurring cash flow per share	7.65	10.05	11.06	11.42	11.85

Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross)	26,652	27,899	29,432	31,011	32,400
Less: Accumulated depreciation	(14,236)	(14,921)	(15,990)	(17,108)	(18,388)
Tangible fixed assets (net)	12,416	12,978	13,442	13,903	14,012
Intangible fixed assets (net)	61	61	61	61	61
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	1	13	13	13	13
Cash & equivalents	8,276	10,745	14,415	17,430	20,940
A/C receivable	2,658	4,408	4,408	4,408	4,408
Inventories	326	362	345	354	377
Other current assets	159	169	170	175	185
Current assets	11,419	15,685	19,339	22,368	25,909
Other assets	362	475	475	475	475
Total assets	24,259	29,212	33,330	36,820	40,470
Common equity	19,705	23,801	27,887	31,193	34,531
Minorities etc.	300	297	358	422	490
Total shareholders' equity	20,005	24,098	28,245	31,615	35,021
Long term debt	63	91	91	91	91
Other long-term liabilities	799	856	856	856	856
Long-term liabilities	862	947	947	947	947
A/C payable	1,085	1,078	1,028	1,055	1,121
Short term debt	0	0	0	0	0
Other current liabilities	2,306	3,089	3,110	3,203	3,381
Current liabilities	3,391	4,167	4,138	4,258	4,502
Total liabilities and shareholders' equity	24,259	29,212	33,330	36,820	40,470
Net working capital	(249)	772	786	680	468
Invested capital	12,591	14,299	14,777	15,132	15,029

* Includes convertibles and preferred stock which is being treated as debt

Per share (THB)

Book value per share	24.76	29.91	35.04	39.20	43.39
Tangible book value per share	24.69	29.83	34.97	39.12	43.32

Financial strength

Net debt/equity (%)	(41.1)	(44.2)	(50.7)	(54.8)	(59.5)
Net debt/total assets (%)	(33.9)	(36.5)	(43.0)	(47.1)	(51.5)
Current ratio (x)	3.4	3.8	4.7	5.3	5.8
CF interest cover (x)	(114.1)	(38.0)	(25.2)	(26.2)	(23.2)

Valuation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	30.2	21.6	19.5	18.9	18.5
Recurring P/E @ target price (x) *	35.4	25.3	22.8	22.1	21.7
Reported P/E (x)	30.2	21.3	19.5	18.9	18.5
Dividend yield (%)	1.7	2.0	2.4	3.1	3.2
Price/book (x)	7.6	6.3	5.4	4.8	4.3
Price/tangible book (x)	7.6	6.3	5.4	4.8	4.3
EV/EBITDA (x) **	19.8	14.6	13.2	12.5	11.6
EV/EBITDA @ target price (x) **	23.5	17.3	15.7	14.9	14.0
EV/invested capital (x)	11.2	9.7	9.2	8.7	8.6

* Pre-exceptional, pre-goodwill and fully diluted ** EBITDA includes associate income and recurring non-operating income

Sources: Bumrungrad Hospital; FSSIA estimates

Bumrungrad Hospital PCL (BH TB)

FSSIA ESG rating



51.21 /100

Exhibit 15: FSSIA ESG score implication

Rating	Score	Implication
★★★★★	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
★★★★★	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
★★★	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
★★	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
★	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 16: ESG – peer comparison

	FSSIA ESG score	Domestic ratings						Global ratings					Bloomberg		
		DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71	--	--	--	4.00	5.00	Certified	High	48.21	--	--	27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00	--	Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21	--	--	--	4.00	4.00	--	Medium	64.29	A	29.00	59.03	27.00	5.08	47.79
CHG	38.25	--	--	--	4.00	5.00	--	High	55.35	--	--	59.57	21.00	2.34	50.24
PR9	54.08	--	Y	Y	5.00	5.00	Certified	High	71.12	--	--	62.39	--	2.43	37.90
PRINC	18.00	--	--	--	4.00	4.00	Certified	--	--	--	--	--	--	--	--
RAM	11.75	--	--	--	3.00	--	--	High	--	--	--	--	--	--	--
THG	18.75	--	--	--	5.00	5.00	--	High	--	--	--	--	--	--	--
VIBHA	20.88	--	--	--	4.00	3.00	Declared	High	--	--	--	--	17.00	--	--

Sources: [SETTRADE.com](https://www.settrade.com); FSSIA's compilation

Exhibit 17: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.85	1.30	1.60	1.49	1.73	3.35	3.58	5.08
BESG environmental pillar score	0.00	1.75	1.75	1.75	1.75	3.21	3.73	3.73
BESG social pillar score	0.18	0.18	0.38	0.38	0.85	3.19	3.25	6.43
BESG governance pillar score	3.25	3.57	4.35	3.81	3.55	3.73	4.07	3.97
ESG disclosure score	31.24	32.94	35.78	35.78	36.40	47.68	47.79	47.79
Environmental disclosure score	0.42	5.53	8.91	8.91	9.76	35.43	35.76	35.76
Social disclosure score	12.03	12.03	17.17	17.17	18.20	26.39	26.39	26.39
Governance disclosure score	81.10	81.10	81.10	81.10	81.10	81.10	81.10	81.10
Environmental								
Emissions reduction initiatives	No	No	No	No	No	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	Yes	Yes	Yes
Climate change opportunities discussed	No	No	No	No	No	No	No	No
Risks of climate change discussed	No	No	No	No	No	No	Yes	Yes
GHG scope 1	—	—	—	—	—	—	—	—
GHG scope 2 location-based	—	—	—	—	—	—	—	—
GHG Scope 3	—	—	—	—	—	—	—	—
Carbon per unit of production	—	—	—	—	—	—	—	—
Biodiversity policy	No	No	No	No	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	—	0	0	0	0	0	0	0
Renewable energy use	—	—	—	—	—	—	—	—
Electricity used	—	—	—	—	—	—	—	—
Fuel used - natural gas	—	—	—	—	—	—	—	—

Sources: Bloomberg; FSSIA's compilation

Exhibit 18: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	No	No	Yes	Yes	Yes
Hazardous waste	—	—	—	—	—	—	—	—
Total waste	—	—	—	—	—	—	—	—
Waste recycled	—	—	—	—	—	—	—	—
Waste sent to landfills	—	—	—	—	—	—	—	—
Environmental supply chain management	No	No	No	No	No	Yes	Yes	Yes
Water policy	No	No	No	No	Yes	Yes	Yes	Yes
Water consumption	—	—	—	—	—	—	—	—
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	Yes	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	No	Yes	Yes	Yes
Consumer data protection policy	No	No	No	No	No	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	—	—	—	—	—	—	—	—
Pct disabled in workforce	—	—	—	—	—	—	—	—
Business ethics policy	No	No	No	No	No	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	—	—	—	—	—	—	—	—
Total recordable incident rate - employees	—	—	—	—	—	—	—	—
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	—	—	3,984	3,980	4,088	3,782	3,455	4,219
Employee turnover pct	—	—	—	—	—	7	7	8
Total hours spent by firm - employee training	—	—	247,805	268,252	283,707	207,353	195,380	234,480
Social supply chain management	No	No	No	No	No	Yes	Yes	Yes
Governance								
Board size	11	11	11	11	10	10	11	11
No. of independent directors (ID)	4	4	4	4	4	4	5	5
No. of women on board	3	3	3	3	3	3	3	3
No. of non-executive directors on board	8	8	9	9	9	9	10	10
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	5	4	6	4	4	7	4	4
Board meeting attendance pct	91	93	97	87	88	87	95	98
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No	No	No	No	No	No	No	No
Age of the youngest director	42	43	49	50	51	52	27	28
Age of the oldest director	75	75	78	79	79	80	78	79
No. of executives / company managers	7	6	6	6	4	4	4	5
No. of female executives	1	2	2	3	3	3	3	3
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	4	4
No. of ID on audit committee	3	3	3	3	3	3	4	4
Audit committee meetings	4	4	4	5	5	4	4	4
Audit meeting attendance %	100	92	92	87	100	100	87	100
Size of compensation committee	3	3	3	3	3	3	3	3
No. of ID on compensation committee	1	1	1	1	1	1	1	1
No. of compensation committee meetings	1	1	5	3	2	2	3	3
Compensation meeting attendance %	100	100	100	100	100	83	100	100
Size of nomination committee	3	3	3	3	3	3	3	3
No. of nomination committee meetings	1	1	5	3	2	2	3	3
Nomination meeting attendance %	100	100	100	100	100	83	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology	Rating																			
The Dow Jones Sustainability Indices (DJSI) By S&P Global	The DJSI World applies a transparent, rules-based component selection process based on the companies' Total Sustainability Scores resulting from the annual S&P Global Corporate Sustainability Assessment (CSA). Only the top-ranked companies within each industry are selected for inclusion.	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.																			
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	SET ESG quantifies responsibility in Environmental and Social issues by managing business with transparency in Governance, updated annually. Candidates must pass the preemptive criteria, with two crucial conditions: 1) no irregular trading of the board members and executives; and 2) free float of >150 shareholders, and combined holding must be >15% of paid-up capital. Some key disqualifying criteria include: 1) CG score of below 70%; 2) independent directors and free float violation; 3) executives' wrongdoing related to CG, social & environmental impacts; 4) equity in negative territory; and 5) earnings in red for > 3 years in the last 5 years.	To be eligible for SETESG inclusion , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. SETESG Index is extended from the SET ESG Ratings companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.																			
CG Score by Thai Institute of Directors Association (Thai IOD)	An indicator of CG strength in sustainable development, measured annually by the Thai IOD, with support from the Stock Exchange of Thailand (SET). The results are from the perspective of a third party, not an evaluation of operations.	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).																			
AGM level By Thai Investors Association (TIA) with support from the SEC	It quantifies the extent to which shareholders' rights and equitable treatment are incorporated into business operations and information is transparent and sufficiently disclosed. All form important elements of two out of five the CG components to be evaluated annually. The assessment criteria cover AGM procedures before the meeting (45%), at the meeting date (45%), and after the meeting (10%). <i>(The first assesses 1) advance circulation of sufficient information for voting; and 2) facilitating how voting rights can be exercised. The second assesses 1) the ease of attending meetings; 2) transparency and verifiability; and 3) openness for Q&A. The third involves the meeting minutes that should contain discussion issues, resolutions and voting results.)</i>	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.																			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. <i>(Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)</i>	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.																			
Morningstar Sustainalytics	The Sustainalytics' ESG risk rating provides an overall company score based on an assessment of how much of a company's exposure to ESG risk is unmanaged. <i>Sources to be reviewed include corporate publications and regulatory filings, news and other media, NGO reports/websites, multi-sector information, company feedback, ESG controversies, issuer feedback on draft ESG reports, and quality & peer reviews.</i>	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. <table><tr><th>NEGL</th><th>Low</th><th>Medium</th><th>High</th><th>Severe</th></tr><tr><td>0-10</td><td>10-20</td><td>20-30</td><td>30-40</td><td>40+</td></tr></table>	NEGL	Low	Medium	High	Severe	0-10	10-20	20-30	30-40	40+									
NEGL	Low	Medium	High	Severe																	
0-10	10-20	20-30	30-40	40+																	
ESG Book	The ESG score identifies sustainable companies that are better positioned to outperform over the long term. The methodology considers the principle of financial materiality including information that significantly helps explain future risk-adjusted performance. Materiality is applied by over-weighting features with higher materiality and rebalancing these weights on a rolling quarterly basis.	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.																			
MSCI	MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities. It uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. <table><tr><td>AAA</td><td>8.571-10.000</td><td rowspan="3">Leader:</td><td rowspan="3">leading its industry in managing the most significant ESG risks and opportunities</td></tr><tr><td>AA</td><td>7.143-8.570</td></tr><tr><td>A</td><td>5.714-7.142</td></tr><tr><td>BBB</td><td>4.286-5.713</td><td rowspan="3">Average:</td><td rowspan="3">a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers</td></tr><tr><td>BB</td><td>2.857-4.285</td></tr><tr><td>B</td><td>1.429-2.856</td></tr><tr><td>CCC</td><td>0.000-1.428</td><td>Laggard:</td><td>lagging its industry based on its high exposure and failure to manage significant ESG risks</td></tr></table>	AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities	AA	7.143-8.570	A	5.714-7.142	BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers	BB	2.857-4.285	B	1.429-2.856	CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks
AAA	8.571-10.000	Leader:	leading its industry in managing the most significant ESG risks and opportunities																		
AA	7.143-8.570																				
A	5.714-7.142																				
BBB	4.286-5.713	Average:	a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers																		
BB	2.857-4.285																				
B	1.429-2.856																				
CCC	0.000-1.428	Laggard:	lagging its industry based on its high exposure and failure to manage significant ESG risks																		
Moody's ESG solutions	Moody's assesses the degree to which companies take into account ESG objectives in the definition and implementation of their strategy policies. It believes that a company integrating ESG factors into its business model and relatively outperforming its peers is better positioned to mitigate risks and create sustainable value for shareholders over the medium to long term.																				
Refinitiv ESG rating	Designed to transparently and objectively measure a company's relative ESG performance, commitment and effectiveness across 10 main themes, based on publicly available and auditable data. The score ranges from 0 to 100 on relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly. <i>(Score ratings are 0 to 25 = poor; >25 to 50 = satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)</i>																				
S&P Global	The S&P Global ESG Score is a relative score measuring a company's performance on and management of ESG risks, opportunities, and impacts compared to its peers within the same industry classification. The score ranges from 0 to 100.																				
Bloomberg	ESG Score	Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.																			
Bloomberg	ESG Disclosure Score	Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.																			

[Rating](#) regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "**CG Score**"; 2) "**AGM Level**"; 3) "**Thai CAC**"; and 4) **THSI**. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Bumrungrad Hospital	BH TB	THB 187.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Bangkok Dusit Medical Services	BDMS TB	THB 23.30	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bangkok Chain Hospital	BCH TB	THB 15.60	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Chularat Hospital	CHG TB	THB 2.28	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Patangsit Healthcare Group	PHG TB	THB 14.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Praram 9 Hospital	PR9 TB	THB 23.20	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 13.40	HOLD	Upside risks to our DCF-based target price include 1) a new Covid wave from a new variant; and 2) big-lot sales of Jin Wellbeing County units. Downside risks include 1) regulatory risks from drug prices and medical bill controls; and 2) a slowdown in international patients due to economic concerns.
Ramkhamhaeng Hospital	RAM TB	THB 20.50	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.
Srivichaivejvivat	VIH TB	THB 7.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 21-Feb-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as $(\text{target price}^* - \text{current price}) / \text{current price}$.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.